Introduction {#s1}
============

Lymphangioleiomyomatosis (LAM) is a rare multisystem disease characterised by lung cysts and lymphatic abnormalities. The disease is almost exclusively restricted to women, of whom it affects around nine per million, and can occur both sporadically and in those with tuberous sclerosis complex (TSC) \[[@C1], [@C2]\]. In LAM, cysts progressively replace the lung parenchyma leading to recurrent pneumothorax and often respiratory failure over a variable period of years \[[@C3]\]. Lymphatic obstruction leads to chyloptysis, chylous effusions and ascites. Around half of patients with sporadic LAM and most with TSC-LAM also have angiomyolipomas, a benign tumour, generally occurring in the kidneys \[[@C2]\]. The lungs and lymphatics of patients are infiltrated by LAM cells: a clonal, metastatic cell with a combined smooth muscle and melanocyte phenotype characteristic of perivascular epithelioid cell neoplasms \[[@C4]\]. LAM cells have biallelic TSC mutations \[[@C5]\] which lead to hyperactivation of the mechanistic target of rapamycin (mTOR), a component of two multiprotein complexes, controlling proliferation, migration, autophagy and metabolism \[[@C6]\].

Most women with LAM lose lung function at an accelerated rate with forced expiratory volume in 1 s (FEV~1~) declining by 70--140 mL per year \[[@C7], [@C8]\]; however, some progress rapidly while others can remain stable for many years \[[@C3], [@C9]\]. Treatment with mTOR inhibitors prevents loss of lung function in most with progressive disease \[[@C8]--[@C10]\]. Recognising progressive disease in individuals with mild lung function impairment is important, although generally requires multiple measurements over a prolonged period \[[@C7]\]. Markers of disease activity are therefore required to predict those at risk of loss of lung function to allow treatment before this occurs. Furthermore, stratification of patients with active disease could reduce the size, duration, cost and feasibility of phase II studies of new therapies.

A number of clinical and serum prognostic factors have been identified. Elevated serum vascular endothelial growth factor (VEGF)-D is associated with both the presence of LAM \[[@C11]\] and more rapid loss of lung function. Presentation with dyspnoea rather than pneumothorax and a response to bronchodilators have been associated with worse outcomes \[[@C12]--[@C14]\], whereas post-menopausal status is associated with slower lung function loss \[[@C7], [@C15]\]. Despite this, it is not possible to accurately predict prognosis within individuals. Here, we used serum proteomics to identify proteins associated with the presence and severity of LAM, and identified that changes in vitamin D binding protein (VTDB) and its gene, *GC* (group-specific component), are associated with disease severity and survival in LAM.

Materials and methods {#s2}
=====================

Patients and sample collection {#s2a}
------------------------------

101 women with LAM and 22 healthy control women were recruited between 2011 and 2016 from the National Centre for LAM (Nottingham, UK) ([figure 1](#F1){ref-type="fig"}). Ethical approval was obtained from the East Midlands Research Ethics Committee (13/EM/0264). All subjects provided written informed consent. A second cohort of 152 women with LAM recruited between 1998 and 2001 in the National Heart, Lung and Blood Institute (NHLBI) LAM Registry (USA) was used for replication and to study long-term survival \[[@C16]\] ([figure 1](#F1){ref-type="fig"}). Baseline chest and abdominal computed tomography, serial lung function, serum, and DNA at recruitment were obtained for all subjects. Clinical assessment, lung function and sample analysis for both cohorts are described in the [supplementary material](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00951-2018.figures-only#fig-data-supplementary-materials). Due to duration of follow-up, all-cause mortality or the need for lung transplant was only available for the NHLBI LAM Registry cohort and was obtained by querying the US National Death Index ([www.cdc.gov/nchs/ndi/index.htm](http://www.cdc.gov/nchs/ndi/index.htm)) and the United Network for Organ Sharing databases ([https://unos.org/data](https://unos.org/data/)). As data on the use of rapamycin was not available for this cohort, outcome data were censored at 2010 before rapamycin was widely used for the treatment of LAM in the USA.

![Enrolment and samples tested: recruitment and access to samples and lung function data in the UK and the USA National Heart, Lung and Blood Institute (NHLBI) lymphangioleiomyomatosis (LAM) cohorts. PFT: pulmonary function test; VTDB: vitamin D binding protein. The UK discovery cohort comprised 50 serum samples from individuals with LAM, the UK replication cohort comprised 27 LAM serum samples and the USA NHLBI LAM Registry cohort comprised 152 serum samples.](ERJ-00951-2018.01){#F1}

Proteomics {#s2b}
----------

70 serum samples (50 LAM and 20 controls) were analysed on a SCIEX (Warrington, UK) TripleTOF 6600 mass spectrometer hyphenated to an Eksigent nanoLC 425 system using the SCIEX SWATH mass spectrometric workflow \[[@C17]\]. Tandem mass spectrometry (MS/MS) spectra were searched using ProteinPilot version 5.0 (SCIEX) with the Swiss-Prot human database ([www.uniprot.org](http://www.uniprot.org/); January 2015) at 1% false discovery rate with an identification focus on biological modifications. SWATH data were aligned to library files in PeakView (SCIEX), uploaded and processed using the SCIEX OneOmics platform \[[@C18]\]. Full details are given in the [supplementary material](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00951-2018.figures-only#fig-data-supplementary-materials).

Serum protein quantification {#s2c}
----------------------------

Serum VTDB, α~1~-acid glycoprotein 1 (A1AG1) and VEGF-D were determined in the UK cohort using Quantikine ELISA kits DVDBP0, DAGP00 and DVED00, respectively (R&D Systems, Abingdon, UK). VTDB in the NHLBI LAM Registry was measured using Quantikine ELISA kit DVDBP0B (R&D Systems).

Genotyping {#s2d}
----------

DNA was extracted from whole blood using the Wizard Genomic DNA Purification Kit (Promega, Southampton, UK). As *GC* genotype varies across populations, genetic analysis was confined to those of European ancestry. 65 UK LAM samples and 168 141 unrelated control women of European ancestry from the UK Biobank ([www.ukbiobank.ac.uk](http://www.ukbiobank.ac.uk/)) were genotyped using the Axiom UK Biobank array (Affymetrix, High Wycombe, UK). Ancestry was determined from *k*-means clustering of the first two principal components from the genome-wide single nucleotide polymorphism (SNP) data \[[@C19]\]. Women from the NHLBI LAM Registry cohort were genotyped using KASP PCR genotyping (LGC Genomics. Hoddesdon, UK) with ancestry obtained by questionnaire.

Statistical analysis {#s2e}
--------------------

Proteins identified by proteomics were considered differentially expressed if they were ≤ −2 or ≥2 log~2~ fold different between groups with a confidence ≥0.7 as described by L[ambert]{.smallcaps} *et al.* \[[@C18]\]. Welch\'s t-test or the Mann--Whitney U-test were used for categorical data; linear regression and Spearman\'s correlation were used for continuous data. *GC* allele frequencies for women with LAM and UK Biobank controls were compared using Chi-squared tests \[[@C20]\]. Survival analyses were performed using Kaplan--Meier plots with differences analysed by the Mantel--Cox log-rank test. Analyses were performed using Prism version 7 (GraphPad, La Jolla, CA, USA) and SPSS version 24 (IBM, Armonk, NY, USA).

Results {#s3}
=======

Discovery cohort and serum proteomics {#s3a}
-------------------------------------

The first 50 UK women with LAM enrolled who were not treated with an mTOR inhibitor and 20 healthy control women formed the discovery cohort. The cohort was divided into more progressive and stable disease based upon a retrospective loss of FEV~1~ of \>50 mL per year over a mean±[sd]{.smallcaps} period of observation of 11±4 years. Those with progressive disease had lower FEV~1~, diffusing capacity of the lung for carbon monoxide (*D*~LCO~) and higher serum VEGF-D values, but were of similar age and disease duration as those with stable disease ([table 1](#TB1){ref-type="table"}).

###### 

Clinical data for cohorts studied

                                 **UK discovery cohort**   **UK replication cohort**   **UK rapamycin-treated group**   **USA NHLBI cohort**   **Healthy controls**              
  ----------------------------- ------------------------- --------------------------- -------------------------------- ---------------------- ---------------------- ----------- -----------
  **Subjects n**                           50                         26                             24                          27                     24               152         22
  **Age years**                         50.6±10.9                  50.9±11.8                     50.3±10.0                   49.4±13.9               46.4±9.7         45.4±9.0    35.0±11.7
  **Disease duration years**            13.9±11.1                  14.2±11.4                     13.5±11.1                    9.1±9.5                13.1±9.5          4.6±4.3       NA
  **Angiomyolipoma**                       72                         77                             67                          55                     54               NT          NA
  **Lymphatic disease**                    16                         15                             17                          23                     25               NT          NA
  **TSC**                                  14                         19                             8                           15                     21               NT          NA
  **Pneumothorax**                         48                         50                             46                          40                     46               NT          NA
  **Post-menopause**                       34                         42                             25                          30                     25               48          NA
  **FEV**~**1**~ **% pred**             68.9±20.6                  76.4±18.9                     60.8±19.5                   77.4±23.4              46.7±14.8         74.1±27.5      NA
  ***D***~**LCO**~ **% pred**           59.8±15.8                  68.9±12.7                     50.0±12.9                   62.9±17.1              43.3±12.3         55.7±25.6      NA
  **VEGF-D pg·mL^−1^**                  1327±1187                   985±833                      1698±1405                   1275±1527              1082±1257            NT        397±125

Data are presented as mean±[sd]{.smallcaps} (at recruitment) or % (present at any time in disease course), unless otherwise stated. NHLBI: National Heart, Lung and Blood Institute; TSC: tuberous sclerosis complex; FEV~1~: forced expiratory volume in 1 s; *D*~LCO~: diffusing capacity of the lung for carbon monoxide; VEGF: vascular endothelial growth factor; NA: not applicable; NT: not available for testing. Disease duration in the UK lymphangioleiomyomatosis cohort was from first symptom to enrolment, while in the NHLBI cohort disease duration was from diagnosis to enrolment. In the NHLBI cohort menopause was assumed if ≥50 years of age.

MS of the 70 serum samples identified 126 proteins, including the serum proteins albumin, haemopexin, acid glycoprotein, immunoglobulins, complement components, clotting factors, proteases and protease inhibitors ([supplementary table E1](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00951-2018.figures-only#fig-data-supplementary-materials)). VTDB levels were 2.6-fold lower (confidence 0.65) in LAM than healthy control women ([supplementary table E2](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00951-2018.figures-only#fig-data-supplementary-materials)). To identify markers of severity we compared the proteomic profiles of those with stable and progressive disease. A1AG1 levels were 3.6-fold higher (confidence 0.70) in those with progressive compared with stable disease. Comparison of pre- and post-menopausal women with LAM did not identify differentially expressed proteins at the pre-specified confidence level.

Serum protein quantification {#s3b}
----------------------------

MS findings were validated using ELISAs for VTDB and A1AG1. Consistent with the proteomic findings, serum VTDB was lower in 50 women with LAM in the UK discovery cohort and 27 women with LAM in the UK replication cohort than in controls (p=0.007 and p=0.002, respectively). For the 77 women in the UK discovery (n=50) and replication cohorts (n=27) combined, VTDB was 273±96 µg·mL^−1^ in LAM and 347±92 µg·mL^−1^ in control women (p=0.002) ([figure 2a](#F2){ref-type="fig"}). When assessed by ELISA, A1AG1 was higher in women with LAM in the discovery and replication cohorts than control women (p=0.04 and p=0.0001, respectively). A1AG1 was 910±478 µg·mL^−1^ for all women with LAM and 619±270 µg·mL^−1^ in control women (p=0.004) ([figure 2b](#F2){ref-type="fig"}).

![Serum vitamin D binding protein (VTDB) and α~1~-acid glycoprotein 1 (A1AG1) in lymphangioleiomyomatosis (LAM) and healthy controls. a) Women with LAM had lower levels of serum VTDB compared with healthy control women (p=0.002). b) Women with LAM had higher levels of serum A1AG1 compared with healthy control women (p=0.004).](ERJ-00951-2018.02){#F2}

VTDB is associated with disease severity {#s3c}
----------------------------------------

VTDB was significantly lower in those with more progressive compared with more stable lung disease at recruitment (progressive 221±89 µg·mL^−1^ *versus* stable 299±90 µg·mL^−1^; p=0.001) ([figure 3a](#F3){ref-type="fig"}). VTDB level was positively associated with percent predicted *D*~LCO~ (p=0.01) but not forced vital capacity (p=0.09) or FEV~1~ (p=0.23) ([figure 3b](#F3){ref-type="fig"}--d). A1AG1 was higher in those with stable compared with progressive disease (stable 1004±525 µg·mL^−1^ *versus* progressive 753±341 µg·mL^−1^; p=0.01) ([supplementary figure E1](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00951-2018.figures-only#fig-data-supplementary-materials)), but was not related to lung function. Levels of VTDB were not associated with age, age at diagnosis, menopausal status, nature of presenting symptom, presence of tuberous sclerosis, angiomyolipomas, lymphatic disease or serum VEGF-D level (data not shown). The distribution of VTDB was similar in the 77 untreated women and 24 women receiving treatment with rapamycin for LAM, whereas A1AG1 was higher in the rapamycin-treated group (treated 1132±474 µg·mL^−1^ *versus* untreated 910±478 µg·mL^−1^; p=0.031) ([supplementary figure E2](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00951-2018.figures-only#fig-data-supplementary-materials)).

![Vitamin D binding protein (VTDB) is associated with disease severity. LAM: lymphangioleiomyomatosis; *D*~LCO~: diffusing capacity of the lung for carbon monoxide; FVC: forced vital capacity; FEV~1~: forced expiratory volume in 1 s. a) Lower levels of serum VTDB are associated with progressive LAM compared with stable LAM (p=0.001). b) VTDB level is positively correlated with *D*~LCO~ % pred (p=0.01). c) VTDB is not associated with FVC % pred (p=0.09). d) VTDB is not associated with FEV~1~ % pred (p=0.23).](ERJ-00951-2018.03){#F3}

Association of *GC* genotypes with LAM and serum VTDB {#s3d}
-----------------------------------------------------

As *GC* genotype varies according to ancestry, genetic analyses were restricted to the 65 individuals in the UK and 145 individuals in the NHLBI LAM Registry cohorts of European origin. Two SNPs within *GC* at rs7041 and rs4588 define the major *GC* haplotypes: 1) *GC1F* where rs7041 (G) and rs4588 (A), 2) *GC1S* where rs7041 (T) and rs4588 (A), and 3) *GC2* where rs7041 (G) and rs4588 (C). The allele frequencies at these SNPs in the UK and NHLBI LAM Registry cohorts did not differ from control women in the UK Biobank or each other ([supplementary table E3](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00951-2018.figures-only#fig-data-supplementary-materials)). In both LAM cohorts, as in the general population, serum VTDB was dependent on *GC* genotype ([supplementary figure E3](http://erj.ersjournals.com/lookup/doi/10.1183/13993003.00951-2018.figures-only#fig-data-supplementary-materials)) \[[@C21]\].

Association of VTDB protein and genotype with outcome {#s3e}
-----------------------------------------------------

From the UK cohort, 91 women with LAM had lung function measured over \>1 year after enrolment (64 untreated and 27 receiving rapamycin for LAM). The mean period of observation was 19 months, corresponding to 144 patient-years of observation. Within the NHLBI LAM Registry cohort, 136 women with untreated LAM had lung function measured over \>1 year after enrolment with a mean period of observation of 40 months, corresponding to 500 patient-years of observation. Serum VTDB was not associated with prospective change in lung function in either cohort ([table 2](#TB2){ref-type="table"}).

###### 

Prospective change in forced expiratory volume in 1 s (FEV~1~) and diffusing capacity of the lung for carbon monoxide (*D*~LCO~) and relationship to vitamin D binding protein (VTDB)

                                                        **UK cohort**    **NHLBI cohort**                                               
  ----------------------------------------------------- --------------- ------------------ ------------ ------------------ ------------ ------------------
  **Subjects n**                                        64                                 27                              136          
  **ΔFEV**~**1**~ **mL per year**                       −32.6±111.2      [ns]{.smallcaps}  24.3±141.4    [ns]{.smallcaps}  −94.7±96.2    [ns]{.smallcaps}
  **Δ*D***~**LCO**~ **mmol·min^−1^·kPa^−1^ per year**   −0.2±0.40        [ns]{.smallcaps}  −0.17±0.23    [ns]{.smallcaps}  −0.23±0.31    [ns]{.smallcaps}
  **VTDB µg·mL^−1^**                                    273±96                             281±105                         255±53.4     

Data are presented as mean±[sd]{.smallcaps}, unless otherwise stated. NHLBI: National Heart, Lung and Blood Institute. ^\#^: p-value for Spearman\'s correlation with serum VTDB. [ns]{.smallcaps}: nonsignificant.

Within the NHLBI LAM Registry cohort, those with low serum VTDB, the AA genotype at rs4588 and TT at rs7041 had the highest rates of loss of FEV~1~ and *D*~LCO~, although not significantly so ([table 3](#TB3){ref-type="table"}). We then examined the relationship of the VTDB axis with time to death or lung transplant in the NHLBI LAM Registry cohort. Although time to death or transplant was not associated with serum VTDB level (p=0.76) ([figure 4a](#F4){ref-type="fig"}) or rs7041 genotype, there was an association with rs4588 genotype. Median time to death or transplant for the AA or AC genotype at rs4588 was 150 months compared with 104 months for CC (p=0.014) ([figure 4b](#F4){ref-type="fig"}). Median time to death or transplant for all haplotypes with an A allele at rs4588 (including *GC1F* and *GC1S* haplotypes) was 150 months compared with 112 months for haplotypes with no A allele present (including *GC2*; p=0.008) ([figure 4c](#F4){ref-type="fig"}).

###### 

Relationship of vitamin D binding protein (VTDB) genotype with clinical features, serum VTDB and change in lung function in the National Heart, Lung and Blood Institute Lymphangioleiomyomatosis (LAM) Registry cohort

                                                         **rs4588 SNP**   **rs7041 SNP**                                                                        
  ----------------------------------------------------- ---------------- ---------------- ----------- ------------------ ------------ ------------ ------------ ------------------
  **Subjects n**                                               11               46            74                              25           57           48      
  **Age at diagnosis years**                                37.4±6.7         42.1±9.9      40.6±9.2    [ns]{.smallcaps}    39.9±7.6     41.8±9.7     40.5±9.6    [ns]{.smallcaps}
  **Age at recruitment years**                              40.9±6.4         47.2±9.4      45.3±8.9                        43.8±7.5     46.4±9.4     45.4±9.3   
  **FEV**~**1**~ **% pred**                                88.0±21.0        78.8±25.2      72.9±29.4   [ns]{.smallcaps}   79.9±26.8    79.0±30.2    72.0±24.0    [ns]{.smallcaps}
  ***D***~**LCO**~ **% pred**                              58.3±17.5        59.5±22.5      57.0±29.3   [ns]{.smallcaps}   56.3±18.2    58.1±30.8    58.9±23.2    [ns]{.smallcaps}
  **VTDB µg·mL^−1^**                                         220±36           245±57        266±52          0.022           233±43       250±57       270±53          0.026
  **ΔFEV**~**1**~ **mL per year**                           −125±142          −78±81        −99±97     [ns]{.smallcaps}    −135±126      −80±84       −94±94     [ns]{.smallcaps}
  **Δ*D***~**LCO**~ **mmol·min^−1^·kPa^−1^ per year**      −0.35±0.23       −0.21±0.36     −0.22±0.3   [ns]{.smallcaps}   −0.26±0.27   −0.20±0.35   −0.26±0.27   [ns]{.smallcaps}

Data are presented as mean±[sd]{.smallcaps} for women with LAM of European ancestry, unless otherwise stated (data for forced expiratory volume in 1 s (FEV~1~) % pred, diffusing capacity of the lung for carbon monoxide (*D*~LCO~) % pred, VTDB and age at recruitment were all at entry to the study; ΔFEV~1~ and Δ*D*~LCO~ are prospective changes from recruitment). Linear regression was used to model the relationship between genotype, clinical factors and VTDB. [ns]{.smallcaps}: nonsignificant.

![Survival analysis for vitamin D binding protein (VTDB) level and *GC* (group-specific component) genotype in the National Heart, Lung and Blood Institute Lymphangioleiomyomatosis Registry cohort. a) Overall time to death or transplant did not differ with serum VTDB level (low (147--221 µg·mL^−1^), medium (222--275 µg·mL^−1^) and high (276--413 µg·mL^−1^)) (p=0.76). b) Individuals with the AA or AC genotype at rs4588 had greater time to death or transplant than those with the CC genotype (p=0.014). c) Haplotypes with an A allele at rs4588 (*GC1F* and *GC1S*) were associated with longer time to death or transplant (p=0.008).](ERJ-00951-2018.04){#F4}

Discussion {#s4}
==========

We have shown for the first time that the VTDB axis is associated with both severity and outcome in women with LAM. VTDB levels were associated with *D*~LCO~ and disease activity at assessment. Those with progressive disease, defined by a loss of FEV~1~ of \>50 mL per year, tended to have lower levels of VTDB than those with more stable disease with a loss of FEV~1~ of \<50 mL per year, despite being matched for age and other clinical manifestations. Haplotypes of *GC* were associated with the time to death or lung transplant. As such, *GC* genotype is the first genetic host factor found to influence transplant-free survival in LAM.

VTDB is a glycosylated α-globulin produced by the liver, kidneys, adipose tissue and neutrophils. Coded for by the *GC* gene on chromosome 4q, two SNPs in exon 11, *i.e.* rs7041 (Glu416Asp) and rs4588 (Thr420Lys), define the three major haplotypes of VTDB: *GC1F* (416Asp/420Thr), *GC1S* (416Glu/420Lys) and *GC2* (416Asp/420Lys), with serum VTDB level related to these SNPs \[[@C21]\]. VTDB binds 25(OH)-vitamin D and 1,25(OH)~2~-vitamin D, although vitamin D levels are far exceeded by the transport capacity of VTDB. Serum levels of VTDB and vitamin D are unrelated in many diseases studied, including chronic obstructive pulmonary disease (COPD) \[[@C22]\]. The *GC* variants have differing affinities for vitamin D; the complexities of the VTDB isoforms, vitamin D and their impact on lung disease are not yet clear \[[@C23]\].

The mechanism relating *GC* genotype and serum VTDB is also unknown. rs7041 and rs4588 are intronic SNPs; neither are in linkage disequilibrium with known promotor or enhancer SNPs, nor are they known to affect protein stability. Factors other than *GC* genotype, including epigenetics, may also influence serum VTDB levels, as although serum VTDB is lower in women with LAM than controls, *GC* genotype in our study was not different.

Our findings reflect the complexity of both the VTDB axis and LAM. We observed that lower serum VTDB was associated with lower lung function and more active lung disease at presentation. As VTDB is not associated with other aspects of the LAM phenotype, including the presence of angiomyolipoma or lymphatic disease, it is likely that the VTDB axis is not related to LAM *per se*, but as in other lung diseases may alter the tissue response to disease. Importantly, *GC* genotype was associated with time to death or lung transplantation. The strongest effect was for the *GC1F* and *GC1S* haplotypes, which were associated with an increase in median survival of \>3 years. Interestingly, these and other *GC* variants associated with improved survival were not those associated with the lowest serum VTDB levels. VTDB is a multifunctional protein which may impact upon the response to lung damage in a number of ways. *GC1F* and *GC1S* are associated with increased macrophage activation over *GC2* \[[@C22]\], and increased macrophage activation may be protective in LAM, either by enhancing protective neutrophil responses or enhancing the chemotactic effect of complement-derived C5a \[[@C24], [@C25]\]. VTDB also acts as an actin scavenging protein and therefore has the potential to influence disease by different mechanisms, including altered innate immunity and tissue repair. Different *GC* haplotypes are already associated with susceptibility to lung disease, with *GC1F* being associated with an enhanced risk of COPD over *GC1S* and *GC2* \[[@C26]\].

These observations underscore the multiple potential functions of VTDB, and how these functions may be related to genotype and the complex relationship with lung disease. The complexity of LAM, a multisystem disease, is also likely to be important. For example, VTDB protein is associated with *D*~LCO~ but not FEV~1~, forced vital capacity or event-free survival. While FEV~1~ is generally used to study the natural history of LAM, *D*~LCO~ is usually impaired before FEV~1~ and may better reflect early parenchymal damage in LAM, with loss of FEV~1~ occurring later due to loss of elastic recoil and premature airway closure brought about by parenchymal damage. Pulmonary vascular disease, host defence, peripheral muscle function and other processes potentially affected by VTDB function may also contribute to survival.

One of the strengths of our study was the use of an unbiased proteomic method that identified VTDB as a protein of interest in LAM. The involvement of the vitamin D axis in other diseases associated with tissue remodelling make our findings biologically plausible \[[@C27]\]. However, our study also has limitations, including the low number of control samples, technical limitations and those inherent in studying rare diseases. First, VTDB was one of only two proteins differentially expressed in the serum of women with LAM and the proteomic methodology used did not identify other LAM markers such as VEGF-D. VEGF-D is expressed at picomolar levels \[[@C28]\], whereas VTDB is present a micromolar levels, suggesting that only relatively abundant serum proteins with robust differences between women with LAM and healthy controls could be detected using this proteomic strategy. It is therefore likely that other potentially useful biomarkers remain undiscovered. Consistent with this, A1AG1, also known as orosomucoid, the other protein linked to the presence of LAM in our proteomic screen, is another relatively abundant plasma α-globulin, comprising 1--3% of plasma proteins. As A1AG1 is an acute-phase protein, already recognised as a biomarker of overall survival in many populations, we did not study it further \[[@C29]\]. As LAM is very rare, studying the disease relies upon cohorts accumulated over longer periods of time. Although both cohorts studied used protocol-driven assessments to capture key data including lung function, there are some differences in the data available for these groups. Although the two cohorts used were similar in terms of age and lung function, prospective change in lung function differed, probably due to the use of rapamycin in the UK cohort resulting in reduced loss of FEV~1~. Conversely, due to time of recruitment, long-term survival prior to rapamycin use can now only be studied in the NHLBI LAM Registry cohort. Current individuals with progressive disease, including those in the UK cohort studied here, tend to be treated with rapamycin \[[@C10]\] and longer periods of observation are needed to study the effect of the VTDB protein or genotype on survival in women with LAM treated with rapamycin.

In conclusion, low levels of VTDB are associated with poor lung function in LAM and *GC* genotypes are associated with long-term outcome. Our findings suggest that the VTDB axis is a host factor that may protect against lung damage in LAM and could be of prognostic significance. Further studies are required to validate our findings and understand how the VTDB isoforms modulate lung damage in LAM and other diseases.
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